ACR 2020 (aka ACR Convergence) is just around the corner, with the opening ceremonies and lecture starting Thursday, November 5th; followed by the full meeting beginning the next morning, Friday November 6th.
But wait.... no one's going, it's all virtual and how will this go down?
Read Article
Yesterday the Food and Drug Administration's (FDA) "Vaccines and Related Biological Products Advisory Committee"
Read Article
Bergman and colleagues have studied a large cohort of US rheumatologists and found that nearly half meet at least one criterion defining "burnout" among physicians.
While attending the annual rheumatology review meeting in 2019 (Rheumatology Winter Clinical Symposium) 128
Read Article
Prospective observational findings from the CORRONA registry of rheumatoid arthritis (RA) patients compared clinical outcomes between initial aggressive therapy using either a tumour necrosis factor inhibitor (TNFi) or a non-TNFi (biological disease-modifying antirheumatic drugs (bDMARDs) and
Read Article
The CDC has analyzed temporal trends in percent positivity by age group in COVID-19 hotspot counties before and after their identification as hotspots. Among 767 hotspot counties identified during June and July 2020, early increases in the percent positivity among persons aged ≤24 years were
Read Article
The Nobel Assembly at Karolinska Institutet has awarded the 2020 Nobel Prize in Physiology or Medicine jointly to Harvey J. Alter, Michael Houghton and Charles M. Rice for the discovery of Hepatitis C virus. These three scientists made a decisive contribution to the fight against blood-borne
Read Article
‘Difficult-to-treat RA’ is an oft-used term that carries various clinical qualities and therapeutic disappointments. A EULAR Task Force was established to develop recommendations for the management of difficult-to-treat rheumatoid arthritis and as a first step, have put forth their definition of
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr Jack Cush reviews the news, journal articles and takes a few Back Talk questions this week:
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Peter Nash drpnash ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
"Fierce, Formidable and Phenomenal" was the tag line used to introduce Vice-Presidential candidate, Kamala Harris. Her introduction followed a review of the increasing role of women in voting, society and politics in America. Has the same been realized by women in academic medicine and
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Topical nonsteroidal anti-inflammatory drugs (NSAIDs) are recommended as first-line therapy in a new guideline for treating acute, non-low back pain from musculoskeletal injuries in outpatient settings.
The clinical guide, released by the American College of Physicians (ACP) and the
Read Article
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Jack Cush updates the news and journal articles from the past week on RheumNow.com, with information on enthesitis, nr-Ax-SpA, UAB, Blockbuster Rheum Drugs and use of ACE inhibitors.
Read Article
Several recent publications have focused on the risk and outcomes of rheumatic disease (RDD) and autoimmune patients who become infected with SARs-CoV-2.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Jack Cush reviews why we all love our rheumatology fellows and our best advice for them stemming from these articles.
Read Article
